Mallinckrodt, the Hazelwood-based pharmaceutical company, has eliminated 5 percent of the positions at a St. Louis plant where workers manufacture contrast imaging products, and 15 percent of its workforce at a pharmaceutical plant in New York. A spokeswoman would not say how many people are employed at the St. Louis and New York plants or how many individuals lost their jobs. Among the reasons given was reduced product demand.
Both net income and net sales were down for Mallinckrodt in its fiscal second quarter, ended March 28, compared with the prior-year period, mainly due to acquisition costs. Mallinckrodt employs about 5,500 people worldwide and about 2,500 in the St. Louis area.